Eun Joo Lee1, Kwang Ho In2, Je Hyeong Kim3, Sang Yeub Lee1, Chol Shin3, Jae Jeong Shim1, Kyung Ho Kang1, Se Hwa Yoo1, Chul Hwan Kim4, Han-Kyeom Kim4, Sang Hoon Lee5, Chang Sub Uhm5. 1. Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University College of Medicine, Seoul. 2. Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University College of Medicine, Seoul. Electronic address: khin@kumc.or.kr. 3. Division of Respiratory and Critical Care Medicine, Department of Internal Medicine, Korea University College of Medicine, Ansan. 4. Department of Pathology, Korea University College of Medicine, Seoul. 5. Department of Anatomy, Korea University College of Medicine, Korea University College of Medicine, Seoul, Korea.
Abstract
RATIONALE: Although cigarette smoking is the most important risk factor for COPD, COPD develops in only a minority of smokers, suggesting a significant genetic role. To solve the underlying pathophysiologic mechanism, it is critical to understand genes and their final product, ie, proteins. We investigated the exclusive proteins from the lung tissues obtained from COPD patients using proteomics. METHODS: Nontumorous lung tissue specimens were obtained from patients who underwent surgery for lung cancer. We included 22 subjects: nonsmokers (n = 8), smokers without COPD (healthy smokers, n = 7), and smokers with COPD (n = 7). Proteins were separated from their spots with two-dimensional polyacrylamide gel electrophoresis and examined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). To validate the proteins from the above procedures, Western blotting and immunohistochemistry were conducted. RESULTS: Twelve protein spots from COPD group significantly increased or decreased compared with the other two groups were chosen for MALDI-TOF-MS analysis. Eight proteins were up-regulated in the COPD group as compared with the nonsmokers. Meanwhile, five proteins from the COPD group were up-regulated and five were down-regulated when compared with healthy smokers. Of these, matrix metalloproteinase (MMP)-13 and thioredoxin-like 2 were significantly increased in the COPD patients by Western blot and immunohistochemistry. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes; however, thioredoxin-like 2 was primarily seen in the bronchial epithelium. CONCLUSIONS: MMP-13 and thioredoxin-like 2 in lungs increased in patients with COPD. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes. In contrast, thioredoxin-like 2 was primarily seen in the bronchial epithelium.
RATIONALE: Although cigarette smoking is the most important risk factor for COPD, COPD develops in only a minority of smokers, suggesting a significant genetic role. To solve the underlying pathophysiologic mechanism, it is critical to understand genes and their final product, ie, proteins. We investigated the exclusive proteins from the lung tissues obtained from COPDpatients using proteomics. METHODS: Nontumorous lung tissue specimens were obtained from patients who underwent surgery for lung cancer. We included 22 subjects: nonsmokers (n = 8), smokers without COPD (healthy smokers, n = 7), and smokers with COPD (n = 7). Proteins were separated from their spots with two-dimensional polyacrylamide gel electrophoresis and examined by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF-MS). To validate the proteins from the above procedures, Western blotting and immunohistochemistry were conducted. RESULTS: Twelve protein spots from COPD group significantly increased or decreased compared with the other two groups were chosen for MALDI-TOF-MS analysis. Eight proteins were up-regulated in the COPD group as compared with the nonsmokers. Meanwhile, five proteins from the COPD group were up-regulated and five were down-regulated when compared with healthy smokers. Of these, matrix metalloproteinase (MMP)-13 and thioredoxin-like 2 were significantly increased in the COPDpatients by Western blot and immunohistochemistry. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes; however, thioredoxin-like 2 was primarily seen in the bronchial epithelium. CONCLUSIONS:MMP-13 and thioredoxin-like 2 in lungs increased in patients with COPD. MMP-13 was mainly expressed in the alveolar macrophages and type II pneumocytes. In contrast, thioredoxin-like 2 was primarily seen in the bronchial epithelium.
Authors: Max Wohlauer; Ernest E Moore; Christopher C Silliman; Miguel Fragoso; Fabia Gamboni; Jeffrey Harr; Frank Accurso; Frank Wright; James Haenel; David Fullerton; Anirban Banerjee Journal: Crit Care Med Date: 2012-09 Impact factor: 7.598
Authors: Ross S Osgood; Brad L Upham; Pierre R Bushel; Kalpana Velmurugan; Ka-Na Xiong; Alison K Bauer Journal: Toxicol Sci Date: 2017-05-01 Impact factor: 4.849
Authors: Yu-Hang Zhang; Michael R Hoopmann; Peter J Castaldi; Kirsten A Simonsen; Mukul K Midha; Michael H Cho; Gerard J Criner; Raphael Bueno; Jiangyuan Liu; Robert L Moritz; Edwin K Silverman Journal: Am J Physiol Lung Cell Mol Physiol Date: 2021-10-20 Impact factor: 5.464
Authors: Elise M Messier; Brian J Day; Karim Bahmed; Steven R Kleeberger; Rubin M Tuder; Russell P Bowler; Hong Wei Chu; Robert J Mason; Beata Kosmider Journal: Am J Respir Cell Mol Biol Date: 2013-05 Impact factor: 6.914
Authors: Luigi De Petris; Maria Pernemalm; Göran Elmberger; Per Bergman; Lotta Orre; Rolf Lewensohn; Janne Lehtiö Journal: Proteome Sci Date: 2010-02-26 Impact factor: 2.480
Authors: Russell P Bowler; Chris H Wendt; Michael B Fessler; Matthew W Foster; Rachel S Kelly; Jessica Lasky-Su; Angela J Rogers; Kathleen A Stringer; Brent W Winston Journal: Ann Am Thorac Soc Date: 2017-12